We expect to generate a significant new sales grow "When used in conjunction with other diagnostic information, our PROGENSA PCA3 assay provides clinically important information that helps physicians and their patients make better, more informed decisions about one of the most vexing problems in prostate cancer diagnosis," said Carl Hull, Gen-Probe's Chairman and Chief Executive Officer. "From a commercial perspective, this is the third of four potential US regulatory approvals that we expect to generate a significant new sales growth cycle for the Company."
https://www.gen-probe.com/news/PressReleaseText.asp?compid=135117&releaseID=1661248
If it's not this quarter, we should see momentum on the next one.There is a lag between sales to patients and when they receive the royalties. I think it's about 6 to 9 months.
Hologic Gen-Probe will have a booth on PCA3 at the EAU congress on march 15-19 to Milan,
The PROGENSA PCA3 urine assay, from Hologic | Gen-Probe, is a highly specific gene-based test to aid in the diagnosis of prostate cancer. Please visit booth B 17 as well as www.pca3.org, to learn more about how the CE-marked PCA3 Assay can more accurately predict biopsy outcomes. Hologic | Gen-Probe is a global leader in the development, manufacture and marketing of nucleic acid testing (NAT) products used for the diagnosis of human disease and blood screening.
https://www.eaumilan2013.org/ (Seach PCA3)